Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States. This launch follows the approval from the U.S. FDA for its Abbreviated New Drug Application. The product is bioequivalent to Edarbi® of Azurity Pharmaceuticals, Inc. and is indicated for the treatment of hypertension in adults to lower blood pressure. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity.
Market Impact and Sales Data
Azilsartan Medoxomil Tablets (RLD Edarbi®) had estimated annual sales of USD 53.5 million in the U.S., according to IQVIA MAT data from April 2026. This launch positions Lupin to capture a significant share of the hypertension treatment market.
About Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, Lupin enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.
Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers globally, with a dedicated workforce of over 24,000 professionals. The company is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
For more information, visit www.lupin.com or follow Lupin on LinkedIn.
Edarbi® is a registered trademark of Takeda Pharmaceutical Company, Ltd.
Logo: https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg
